Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy launches authorised omeprazole generic in US

This article was originally published in Scrip

Executive Summary

Ranbaxy Laboratories' US subsidiary has launched an authorised generic of omeprazole 40mg capsules under an agreement withAstraZeneca Pharmaceuticals. Omeprazole 40mg, a generic version of AstraZeneca's Prilosec, is used to treat acid-related disease, including gastric ulcer and Zollinger-Ellison syndrome. Prilosec 40mg reported sales of $204.2 million in the US for the 12 months to March 2008. Ranbaxy Laboratories, which is in the process of being acquired by Daiichi Sankyo launched its first authorised generic, verapamil SR, under an agreement with FSC Laboratories last year. Verapamil SR is a generic version of FSC Laboratories' calcium ion antagonist, Isoptin SR.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC031623

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel